Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4–7. Recent responder subgroup analyses in the phase III ENHANCE study show a large effect size in terms of an increase of 20.58 points on the patient-reported 12-item MS Walking Scale in the 43% of patients classified as responders to PR-fampridine, corresponding to a standardized response mean of 1.68. Use of PR-fampridine in clinical practice varies across Europe, depending partly on whether it is reimbursed. A group of European MS experts met in June 2017 to discuss their experience with using PR-fampridine, including their views on the patient population for treatment, assessment of treatment response, re-testing and retreatment, and stopping criteria. This article summarizes the experts’ opinions on how PRfampridine can be used in real-world clinical practice to optimize the benefits to people with MS with impaired walking ability.
| Identifer | oai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:35544 |
| Date | 05 November 2019 |
| Creators | Albrecht, Philipp, Bjørnå, Ingrid Kristine, Brassat, David, Farrell, Rachel, Feys, Peter, Hobart, Jeremy, Linnebank, Michael, Hupperts, Raymond, Magdič, Jožef, Oreja-Guevara, Celia, Pozzilli, Carlo, Vasco Salgado, Antonio, Ziemssen, Tjalf |
| Publisher | Sage |
| Source Sets | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Language | English |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, doc-type:article, info:eu-repo/semantics/article, doc-type:Text |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | 1756-2864, 10.1177/1756286418803248 |
Page generated in 0.0111 seconds